Clinical trials: Drug Drug Interaction Study
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants
Effect of BMS-986165 on the Blood Levels of Metformin
The purpose of this study is to investigate the effects of BMS-986165 on the drug levels of metformin in healthy participants.
- Trial name
- NCT04671953
- Testing
- BMS-986165, Metformin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period, crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of…
- Trial name
- NCT03376529
- Testing
- SPR741, Ceftazidime, Piperacillin/tazobactam
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Healthy
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much…
- Trial name
- NCT06165146
- Testing
- Repaglinide, Pirtobrutinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects
Study of a drug drug interaction between Paroxetine and PF-00299804.
- Trial name
- NCT01318031
- Testing
- Period 1, Period 2
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate
The primary objective of the drug-drug interaction study is to evaluate any drug interaction between the CYP2D6 substrate metoprolol and pyronaridine-artesunate in healthy volunteers.
- Trial name
- NCT01523002
- Testing
- Metoprolol and pyronaridine-artesunate, pyronaridine-artesunate
- Where
- Switzerland
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Metabolic Disease
Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03395470
- Testing
- PXL770, Rosuvastatin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Hypertension (HTN), Vascular Diseases
The BASIC-S Feasibility Study for Vascular Risk Reduction
Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging.
- Conditions
- Hypertension (HTN), Vascular Diseases, Stroke, Dementia
- Trial name
- BASIC-S (NCT07755631)
- Testing
- BASIC-S Intervention, Standard / Usual Care
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Andrew Appleton
Healthy Subjects
Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P glycoprotein [Pgp] inhibitor) on the pharmacokinetics…
- Trial name
- NCT02947711
- Testing
- E2027, Diltiazem ER
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Healthy Subjects
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.
- Trial name
- NCT01561963
- Testing
- Apremilast, Rifampin Oral Capsules, Rifampin IV Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
To evaluate the pharmacokinetic interaction between tegoprazan and combination of Amoxicillin, Clarithromycin and bismuth in healthy adult volunteers.
- Trial name
- NCT05915871
- Testing
- Tegoprazan, Bismuth, Amoxicilli
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
HIV, Hypercholesterolaemia
Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.
Dyslipidemia is highly prevalent among patients with HIV infection and contributes to the increased cardiovascular disease risk in this patient population.
- Trial name
- AVIATOR (NCT01779687)
- Testing
- raltegravir, Atorvastatin
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy Volunteers
Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants
The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.
- Trial name
- NCT07223671
- Testing
- Repotrectinib, Metformin, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
QT-prolongation
Drug Interactions With Risk of QT-prolongation in a General Hospital
In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation.
- Trial name
- NCT02043912
- Testing
- Haloperidol
- Where
- Belgium
- Volunteers
- 222 people
- Sponsor
- KU Leuven
Healthy Volunteers
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.
- Trial name
- NCT00783484
- Testing
- PF-03716539, Midazolam, Midazolam + PF-03716539 (100 mg)
- Where
- Belgium
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Solid Tumours
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
This will be an open-label, randomised, 2 part (Part A and Part B), 2 treatment (savolitinib alone or in combination with famotidine), crossover study in healthy, non Japanese, male subjects, performed at a single study centre.
- Trial name
- NCT04179071
- Testing
- Savolitinib, Famotidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.
- Trial name
- NCT01220232
- Testing
- Abacavir/Lamivudine, Lersivirine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs
- Trial name
- NCT05121714
- Testing
- Caffeine, ABX464, Fluvoxamine
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Abivax S.A.
Healthy
Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects
This is an open-label sequential pharmacokinetic study in 16 healthy glucose-6-phosphate dehydrogenase (G6PD) normal Thai subjects at Faculty of Tropical medicine, Mahidol university.
- Trial name
- NCT02324738
- Testing
- Mefloquine and Dihydroartemisinin-piperaquine, Wash-out period, Mefloquine
- Where
- Thailand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Opioid-Related Disorders, Heroin Dependence
Study of Computer-Based Treatment for Drug Dependence
The purpose of this study is to evaluate the whether an automated telephone-based system is useful and helpful for opioid dependent patients receiving buprenorphine in primary care.
- Trial name
- RLSS (NCT01315184)
- Testing
- Recovery Line Support System
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.